Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C
Post# of 421
(Total Views: 110)
Posted On: 04/11/2024 6:26:33 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
- Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO
- Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company
- The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will lead Lexaria’s financial operations, mainly as it looks to double down on GLP-1 human clinical studies for the 2024 calendar year (https://nnw.fm/R6bzx ).
Nelson delivers over 15 years of corporate finance and operations experience within the life sciences industry. Having worked in key organizations such as Rain Oncology, Inc., a late-stage precision oncology biotech company, Lexaria’s management is confident that his skills will be of tremendous value to the company and its growth. Nelson has also served in various roles at Rigel Pharmaceuticals, Inc., including Vice President Finance. He was also a vital member of the executive team that developed and launched TAVALISSE(R) to treat chronic immune thrombocytopenia.
“Nelson’s deep financial leadership experience will be instrumental to the execution of Lexaria’s long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet needs,” noted Chris Bunka, Lexaria’s CEO.
This appointment follows Lexaria’s recent move to hire a contract research organization for its second GLP-1 human pilot study. The study will explore the company’s patented DehydraTECH(TM) technology for the improved delivery of glucagon-like peptide 1 (“GLP-1”) drugs used to treat type 2 diabetes and weight loss. Nelson will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company.
Nelson is optimistic about joining the company, citing DehydraTECH’s potential and proven track record.
“Lexaria has a significant opportunity in continuing its pursuit as a global innovator in drug delivery platforms as proven by the strong potential of DehydraTECH in GLP-1 and hypertension,” he noted. “I’m excited to join the team and look forward to contributing to the company’s progress in GLP-1 and other areas,” he added.
This appointment affirms Lexaria’s commitment to actualize the roadmap detailed earlier in the year, and its confidence in the direction it has taken to focus on GLP-1 studies.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO
- Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company
- The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will lead Lexaria’s financial operations, mainly as it looks to double down on GLP-1 human clinical studies for the 2024 calendar year (https://nnw.fm/R6bzx ).
Nelson delivers over 15 years of corporate finance and operations experience within the life sciences industry. Having worked in key organizations such as Rain Oncology, Inc., a late-stage precision oncology biotech company, Lexaria’s management is confident that his skills will be of tremendous value to the company and its growth. Nelson has also served in various roles at Rigel Pharmaceuticals, Inc., including Vice President Finance. He was also a vital member of the executive team that developed and launched TAVALISSE(R) to treat chronic immune thrombocytopenia.
“Nelson’s deep financial leadership experience will be instrumental to the execution of Lexaria’s long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet needs,” noted Chris Bunka, Lexaria’s CEO.
This appointment follows Lexaria’s recent move to hire a contract research organization for its second GLP-1 human pilot study. The study will explore the company’s patented DehydraTECH(TM) technology for the improved delivery of glucagon-like peptide 1 (“GLP-1”) drugs used to treat type 2 diabetes and weight loss. Nelson will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company.
Nelson is optimistic about joining the company, citing DehydraTECH’s potential and proven track record.
“Lexaria has a significant opportunity in continuing its pursuit as a global innovator in drug delivery platforms as proven by the strong potential of DehydraTECH in GLP-1 and hypertension,” he noted. “I’m excited to join the team and look forward to contributing to the company’s progress in GLP-1 and other areas,” he added.
This appointment affirms Lexaria’s commitment to actualize the roadmap detailed earlier in the year, and its confidence in the direction it has taken to focus on GLP-1 studies.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)